Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479176 | 0.86 | CNR2 (0.52) | CNR2CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL4493023 | 0.81 | CNR2 (0.73) | CNR2CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL4475764 | 0.80 | CNR2 (0.53) | CNR2CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL4471993 | 0.76 | MAPT (0.58) | CNR2CYP2C9CYP2C19CYP1A2SYK | |
| SCHEMBL3378679 | 0.75 | CNR2 (0.71) | CNR2CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL13672511 | 0.75 | CNR2 (0.74) | CNR2CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL3380609 | 0.74 | CNR2 (0.71) | CNR2CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL3378827 | 0.74 | CNR2 (0.71) | CNR2CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL6471548 | 0.73 | CNR2 (0.74) | CNR2CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL3379907 | 0.73 | CNR2 (0.54) | CNR2CYP2C9CYP2C19CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264452-A1 | 2-(Phenylamino)-Pyrimidin-5-Amides As Cannabinoid 2 Receptors Modulators for the Treatment of Immune or Inflammatory Disorders | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| EP-1711475-A1 | 2-(PHENYLAMINO)-PYRIMIDIN-5-AMIDES AS CANNABINOID 2 RECEPTORS MODULATORS FOR THE TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS. | GLAXO GROUP LIMITED (GB) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005075440-A1 | 2- (PHENYLAMINO) -PYRIMIDIN-5-AMIDES AS CANNABINOID 2 RECEPTORS MODULATORS FOR THE TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264452-A1 | 2-(Phenylamino)-Pyrimidin-5-Amides As Cannabinoid 2 Receptors Modulators for the Treatment of Immune or Inflammatory Disorders | CNR2, CNR1, P2RY2 | CNR2 1/4885CYP2C9 1051/4885CYP2C19 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.